Quantcast
Last updated on April 17, 2014 at 8:50 EDT

Latest Azelastine Stories

2013-09-17 12:29:20

Fall Allergy Capitals Report Ranks Most Challenging Cities for Allergies LANDOVER, Md., Sept. 17, 2013 /PRNewswire-USNewswire/ -- This fall could be a perfect storm for allergy sufferers, as global warming conditions boost ragweed levels and fall storms and tornadoes disperse allergens and outdoor mold, according to the Asthma and Allergy Foundation of America (AAFA). The 2013 Fall Allergy Capitals(TM) report released today by AAFA ranks the most challenging cities to live in with allergies...

2009-09-02 07:07:00

SOMERSET, N.J., Sept. 2 /PRNewswire/ -- Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies. ASTEPRO Nasal Spray 0.15% relieves rhinitis symptoms,...

2009-01-15 07:00:00

ASTEPRO(TM) (azelastine hydrochloride) Nasal Spray Hits U.S. Pharmacies SOMERSET, N.J., Jan. 15 /PRNewswire/ -- This allergy season, a new medication is available to manage the symptoms of seasonal allergic rhinitis, a condition that impacts as many as 40 million people in the United States. ASTEPRO Nasal Spray contains azelastine in a unique vehicle formulated for enhanced patient benefits. Azelastine is the active ingredient in ASTELIN(R) (azelastine hydrochloride), a leading...

2008-10-28 06:00:28

Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation. Anders Lonner, CEO of Meda, said: "This product has the potential to become the first once-a-day nasal antihistamine in the US. Beside better tolerance with the new formulation it could also mean better compliance for patients. The product would contribute...

2008-10-17 03:00:16

Regulatory News: Meda AB (STO:MEDAA): The U.S. Food and Drug Administration (FDA) has approved Astepro - the new formulation of Astelin. Astepro Nasal Spray is an improvement over the marketed Astelin Nasal Spray and is better tolerated by patients using the new spray. The active substance in these products is azelastine - the leading nasal antihistamine in the treatment of rhinitis in the U.S. Astepro is now approved for treatment of seasonal allergic rhinitis. Fewer reports...

2008-08-05 12:01:07

Meda has submitted the registration application to the FDA for azelastine nasal spray in the new formulation with extra strength. The application seeks approval to treat symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. The new formulation is patent pending. Six Phase III studies evaluating efficacy and safety and long term safety have been conducted involving about 1,600 patients treated with azelastine extra strength. The higher strength has been shown to offer...

2008-08-04 03:00:32

Regulatory News: Meda AB (STO:MEDAA): The registration application for azelastine nasal spray in the new formulation with Extra Strength has been submitted to the US Food and Drug Administration (FDA), seeking approval to treat symptoms of Seasonal Allergic Rhinitis and Perennial Allergic Rhinitis. The new formulation is patent pending. Six phase III studies evaluating efficacy and safety and a long term safety have been conducted involving about 1,600 patients treated with...

2008-07-09 09:01:02

Meda has announced that the FDA has approved its registration application for azelastine eye drops in unit dose. The substance azelastine is an antihistamine and the eye drop formulation is approved for treatment of allergic conjunctivitis in adults and pediatrics. Meda is conducting a broad development program for the azelastine substance, both as azelastine eye drops and azelastine nasal spray. Azelastine eye drops sample is one part of that development program.

2008-07-08 09:01:11

Regulatory News: The U.S. Food and Drug Administration (FDA) has approved Meda's (STO:MEDAA) registration application for azelastine eye drops in unit dose (Optivar Unit Dose). The substance azelastine is an antihistamine and the eye drop formulation is approved for treatment of allergic conjunctivitis in adults and pediatrics. Meda is conducting a broad development program for the azelastine substance, both as azelastine eye drops and azelastine nasal spray. Azelastine eye drops...